Eli Lilly Q3 2026 Earnings: A Data‑Driven Look at Results, Valuation, and Catalysts

Executive Viewpoint: Large-Q3 Beat, Growing GLP‑1 Momentum, with a Rich Valuation

Eli Lilly delivered a standout third quarter, propelled by continued strength in GLP‑1 weight‑loss and diabetes therapies. Revenue and earnings surpassed expectations, prompting Lilly to raise its full‑year guidance. The improvement was tempered by notable deal charges, which the company described as $4.57 per share in the quarter, offsetting the raised guidance by an equivalent amount at the midpoint. This combination—strong top-line momentum and meaningful one‑time charges—shapes a nuanced view of the earnings quality going forward.

Beyond the core franchises, Lilly announced its agreement to acquire Merida Biosciences, signaling a deliberate push into new autoimmune and allergic disease therapies. The stock reaction was constructive in the near term, with premarket strength reflecting investor optimism about Lilly’s growth trajectory and capital‑allocation strategy.

Q3 Highlights: Revenue, EPS, and GLP‑1 Performance

Key quarterly figures show substantial upside versus consensus. Earnings per share came in at $7.48 on an adjusted basis, versus a $6.26 expectation, underscoring the resilience of Lilly’s core growth engine. Reported revenue totaled $24.40 billion, ahead of StreetAccount expectations of about $22.61 billion. On a GAAP basis, net income was $6.45 billion, or $7.22 per share, which includes the $4.57 per share deal charges. Excluding those one‑time items tied to intangible assets and other adjustments, Lilly reported $7.48 per share in the quarter.

Mounjaro continued to drive the bulk of Lilly’s growth, with worldwide revenue of $10.72 billion in the quarter, including roughly $5.0 billion in the U.S. The international component for Mounjaro rose 93% year over year. Zepbound generated $5.35 billion in quarterly sales, up 49% from the prior year, with the U.S. contributing the vast majority of those sales. Foundayo, Lilly’s newer obesity pill, posted $184 million in U.S. sales for the quarter, falling short of StreetAccount’s approximately $229 million estimate and analyst expectations.

Foundayo’s performance matters because it represents Lilly’s first full quarter of revenue from the GLP‑1 pill, which competes directly with Novo Nordisk’s oral GLP‑1 offering that launched in January. Overall market leadership remains favorable: Lilly held about 63% of the U.S. obesity and diabetes GLP‑1 market in Q3, with Novo Nordisk at 36.6%. Internationally, Lilly commanded 58.4% share versus Novo’s 41.6%.

Guidance Lifted and the Nature of Deal Charges

The company raised its 2026 revenue outlook to a range of $91 billion to $92 billion, up from the prior guide of $85 billion to $87 billion. It also nudged full‑year adjusted EPS to a band of $35 to $36, versus the previous $35.50 to $36.50. At the midpoint, the underlying profit guidance was lifted by $4.07 per share, yet this improvement is offset by $4.57 per share in deal charges recognized in the quarter. This structure leaves investors with higher earnings potential on an adjusted basis, but still a meaningful non‑recurring charge that reduces reported earnings for the period.

In the hours after the release, Lilly’s stock traded higher in premarket activity, reflecting investor relief that the growth narrative remains intact even as dealmaking accelerates. The commentary around deal charges aligns with ongoing M&A activity, including the Merida Biosciences acquisition, which supports the argument that Lilly is using its cash flow to expand the portfolio and extend its competitive moat.

GLP‑1 Franchise: How Shifts in Pricing, Volume, and Mix Shape Growth

The GLP‑1 portfolio remains the centerpiece of Lilly’s growth story. Mounjaro (tirzepatide) posted worldwide revenue of $10.72 billion in the quarter, with U.S. sales around $5.0 billion. The international lift of 93% underscores the drug’s global momentum, supported by strong volume growth and some price pressure in the U.S. Zepbound (dulaglutide) delivered $5.35 billion in revenue, up 49% year over year, as demand remained robust even as realized prices declined by around 7% during the period. Foundayo, Lilly’s newest entrant in obesity, contributed $184 million in U.S. sales, a result that missed the StreetAccount forecast and investor expectations for the quarter, highlighting the competitive challenge posed by Novo’s oral GLP‑1 offering launched earlier in the year.

To put these figures in context, Lilly’s U.S. revenue rose 34% year over year to $15.1 billion, driven by a 41% volume increase across its GLP‑1 portfolio while prices declined about 7%. International revenue surged 47% to $9.3 billion, reflecting broad geographic adoption and stronger demand outside the U.S. The mix shift toward higher‑growth GLP‑1 products continues to underpin Lilly’s top‑line resilience amid pricing headwinds in the domestic market.

Market Access and Competitive Position: Medicare, Market Share, and International Reach

Expanded U.S. coverage for obesity care under Medicare’s GLP‑1 pilot program started in July, with a potential catalyst effect for demand if coverage becomes permanent. While the article does not provide quantified impact from the Medicare program, the pilot is cited as a driver of broader access to obesity therapies and may influence payer dynamics over time. Lilly’s U.S. market leadership remains pronounced, capturing about 63% of the obesity and diabetes GLP‑1 market in Q3, compared with Novo Nordisk’s 36.6% share. Internationally, Lilly held 58.4% of the GLP‑1 market versus 41.6% for Novo Nordisk, highlighting Lilly’s strong international footprint in this fast‑growing category.

Insider Activity and Management’s View of Valuation

Insider trading activity emerged as a talking point in the aftermath of the quarter. In August 2026, several Lilly executives sold shares at prices in the low to mid‑$1,100s range, including Patrik Jonsson selling 6,500 shares at $1,175.10, Anat Hakim selling 5,000 and 10,000 shares at $1,190 each, Anat Hakim again on August 11, 2026 at $1,190, and other executive sales at similar levels. Analysts sometimes interpret such activity as diversification or liquidity management, but patterns and size can warrant closer monitoring for investors concerned about timing and valuation alignment.

Retatrutide Outlook and Foundayo Progress

Retatrutide is Lilly’s next‑generation obesity drug, and data from Phase 3 trials has attracted attention for showing “more than double the weight loss” versus Ozempic at the highest approved dose, according to Seeking Alpha and Morningstar coverage. These results, if confirmed through regulatory review and patient access, could extend Lilly’s competitive moat beyond 2026 and influence long‑term growth expectations. In the near term, Foundayo’s launch and ramp remain a crucial test for adoption in the U.S. market, particularly as Novo’s oral competitor enters the same space and competes for first‑line prescriptions. The quarter’s Foundayo miss underscores the need to monitor launch timing, payer approvals, and competitive dynamics as Lilly weighs next steps for the product line’s scale and pricing strategy.

Bull Case vs. Bear Case: Framing the Risk/Reward

The strongest argument for Lilly hinges on its leadership position in the GLP‑1 wave and the potential for retatrutide to extend its growth runway. Bulls emphasize Lilly’s market dominance in Mounjaro and Zepbound, the expanding international footprint, and the strategic use of cash flow to pursue accretive deals such as Merida Biosciences. The growth trajectory remains supported by a robust pipeline and a favorable regulatory environment, with Medicare coverage expansion acting as a potential accelerator for demand growth in obesity care.

But there are credible counterpoints. The GLP‑1 leadership is already richly valued by the market, with Lilly trading at a trailing P/E around the mid‑40s and a premium to peers like Novo Nordisk and Merck on several metrics. The Foundayo revenue miss in the latest quarter points to execution risks in launching new therapies, competition from Novo’s oral GLP‑1, and potential payer constraints. Additionally, the deal charges of $4.57 per share weigh on reported earnings and raise questions about the sustainability of earnings quality if dealmaking accelerates in future periods. Insiders’ substantial sales in August 2026 add another layer of caution for investors, though they can reflect diversification rather than a negative view of the business if the broader growth thesis remains intact.

Viewed through a decision‑oriented lens, the bull case is strongest for investors who prize Lilly’s core growth engine, scalable international expansion, and the upside from retatrutide and related programs. The bear case centers on a high valuation multiple, potential near‑term pressure from competitive dynamics, and the risk that one‑time deal charges or slower Foundayo execution could erode near‑term earnings visibility. A balanced decision will hinge on the trajectory of Mounjaro and Zepbound demand, the acceptance of Foundayo, the timeline for Medicare coverage outcomes, and how the company monetizes its pipeline via disciplined capital allocation.

Valuation Context: How Lilly Stacks Up Against Peers

Relative valuation matters for investors deciding whether Lilly’s premium is justified. A peer context from independent sources highlights Lilly’s current position relative to Novo Nordisk (NVO) and Merck (MRK). Morningstar’s valuation snapshot shows Lilly trading at a trailing P/E around 40.9x, P/S around 14.5x, and a price-to-book around 33.7x, with an EV/EBITDA near 33.5x. By contrast, Novo Nordisk exhibits a much lower trailing P/E around 8.5x and a P/S near 3.3x, signaling a different growth outlook and risk profile. Merck’s trailing P/E sits in the low‑40s, consistent with a high‑growth pharma narrative in the current environment.

Further context from market data places Lilly’s forward multiple around the mid‑20s (approx. 26.8x for the forward P/E), while Novo Nordisk and Merck typically trade with lower trailing multiples, reflecting the distinct growth trajectories and competitive dynamics. A concise way to view the landscape is that Lilly’s premium P/E and P/S imply strong growth expectations from GLP‑1 leadership, retatrutide upside, and a diversified pipeline, but they also signal higher sensitivity to growth deceleration or any missteps in Foundayo execution. In this sense, valuation is a reflection of the growth narrative as of Q3 2026, with peer context indicating Lilly remains distinctively expensive relative to Novo Nordisk, yet potentially justified if the next phase of growth unfolds as anticipated.

Interpretation: Lilly’s multiples reflect a premium for growth in GLP‑1 therapies and pipeline potential. The peers’ figures illustrate a wide dispersion, with Novo Nordisk trading at much lower multiples on traditional measures, consistent with a different growth trajectory and pricing power in obesity/diabetes franchises. For readers considering valuation discipline, this peer context is essential to gauge whether Lilly’s growth premium is warranted relative to its closest competitors and to set reasonable expectations for multiple reversion or outperformance.

Risks and Near‑Term Catalysts

Near term, investors should monitor the sustainability of GLP‑1 demand in Mounjaro and Zepbound, competitive threats from Novo’s oral GLP‑1, and any shifts in U.S. pricing dynamics following the pricing deal with the prior administration. Foundayo’s trajectory will be a key test of Lilly’s ability to translate new products into material revenue, particularly in the context of Novo’s competing offering. The Medicare pilot could be a meaningful catalyst, but its ultimate impact depends on whether the program is extended or made permanent. In addition, deal charges add an earnings‑quality dimension to the story, as they are tied to dealmaking activity and could recur if M&A accelerates. Insider selling could also merit monitoring as part of a broader assessment of management confidence and valuation alignment.

Investor Takeaways and Practical Implications

Bottom line: Lilly remains a dominant growth platform in GLP‑1 therapies, supported by strong Mounjaro and Zepbound demand and a strategic push into next‑generation therapies. The raised guidance reflects confidence in the growth trajectory, while the deal charges remind investors that part of the near‑term upside is offset by non‑recurring items. Relative valuation remains premium‑driven, with Lilly trading well above Novo Nordisk on several metrics, underscoring the market’s expectations for continued outperformance. Key near‑term inputs to watch include the Foundayo ramp, retatrutide progress, Medicare coverage outcomes, and any updates on the Merida Biosciences integration and other strategic deals. If those dynamics play out as hoped, Lilly could justify its premium multiple; if not, investors may demand faster progress on the pipeline and a clearer path to sustainable profitability beyond the current quarter’s one‑off charges.

Conclusion: A Growth Engine With a Clear Path—and a Priced‑In Premium

Lilly’s Q3 2026 results reinforce the core narrative: a powerful GLP‑1 flight deck, ongoing international expansion, and a capital‑allocation machine turning profits into dealmaking. The raised full‑year guidance signals management’s confidence in sustained demand for Mounjaro and Zepbound, while the Merida Biosciences deal expands the company’s portfolio of therapeutic opportunities. At the same time, the $4.57 per share in quarterly deal charges and the strong market premium invite scrutiny about earnings quality and valuation, particularly if Foundayo’s launch momentum disappoints or if Medicare coverage dynamics shift. For investors, the thesis remains compelling but highly data‑dependent: the next few quarters will be pivotal in validating the durability of growth, the effectiveness of the new organizational structure, and the extent to which retatrutide can extend Lilly’s competitive moat beyond 2026.